CompletedNot applicableNCT03561025
Diagnostic Potential of PET/MRI in Cardiac Sarcoidosis
Studying Sarcoidosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- St. Olavs Hospital
- Principal Investigator
- Edmund SøvikSt. Olavs Hospital
- Intervention
- 18F-FDG-PET/MRI(diagnostic_test)
- Enrollment
- 33 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2018 – 2020
Study locations (1)
- St Olav University Hospital, Dept Radiology and Nuclear Medicine, Trondheim, Norway
Collaborators
Norwegian University of Science and Technology · University Hospital, Essen
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03561025 on ClinicalTrials.govOther trials for Sarcoidosis
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07498842Corticosteroid Tapering in SarcoidosisRoyal Brompton & Harefield NHS Foundation Trust
- RECRUITINGNANCT07073963Virtual Patient Groups for Sarcoidosis Associated FatigueThe Cleveland Clinic
- RECRUITINGPHASE2NCT07159074Repurposing Tilmanocept for Cardiac SarcoidosisDuke University
- RECRUITINGPHASE2NCT06978725A Phase 2 Study of the Safety and Efficacy of Brepocitinib in Adults With Cutaneous Sarcoidosis (BEACON)Priovant Therapeutics, Inc.
- RECRUITINGNANCT05954507Evaluation of the Prognostic Value of PET/MRI in Cardiac SarcoidosisAssistance Publique - Hôpitaux de Paris
- RECRUITINGPHASE2NCT06660732Rilonacept in Subjects With Cardiac SarcoidosisMayo Clinic
- RECRUITINGNANCT07384897Immune Cells Role in Lung Cancer and Their Use in Anticancer Immunotherapies and Inflammatory Lung DiseaseUniversité Catholique de Louvain
- RECRUITINGNCT06510894Diagnostic Utility of SGLT1/2 Inhibition to Facilitate Myocardial Glucose SuppressionUniversity of Pennsylvania